Clinical Trials for To Evaluate the Scaling Clinical Study of AAV2-RPE65 Gene Therapy Agent (LX101) in Patients With Congenital Amaurosis (LCA)

An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA

NCT ID: NCT06024057

This clinical trial is studying a new treatment called AAV2-RPE65 gene therapy (LX101) for patients with a rare eye condition known as congenital amaurosis (LCA), which can cause severe vision loss...